Denali Therapeutics (DNLI) Short Interest & Short Float | Updated Sep 2026
Denali Therapeutics (DNLI) currently has a short interest of 17.14 million shares, representing 11.87% of its public float, which is a 2.99% increase from the previous report. The short interest ratio is 12.0 days to cover, indicating a significant level of pessimism among investors. The article provides a historical overview of DNLI's short interest data, along with explanations of key metrics and comparisons to other biotechnology companies.
Bank of America Corp DE Buys New Position in Denali Therapeutics Inc. $DNLI
Bank of America Corp DE has acquired a new stake of 1.23 million shares in Denali Therapeutics Inc. (NASDAQ:DNLI) during the second quarter, valued at approximately $31.7 million, representing 0.77% of the company. Institutional investors now own 92.92% of Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases. Analysts currently have a "Moderate Buy" consensus rating for DNLI, with an average price target of $35.85, despite the company reporting a quarterly loss that missed estimates, though revenue exceeded expectations.
Denali Therapeutics director sells $261,928 in stock
Nancy Thornberry, a director at Denali Therapeutics Inc. (NASDAQ:DNLI), sold 11,439 shares of common stock for $261,928 on September 2, 2026, executed under a Rule 10b5-1 trading plan. Following the sale, Thornberry directly holds 19,686 shares, including unvested Restricted Stock Units. This transaction occurred as Denali's stock has seen significant year-to-date and annual gains despite a recent revenue miss for Q2 2026 and the launch of its first approved medicine, AVLAYAH.
Denali Therapeutics director sells $261,928 in stock By Investing.com
Nancy Thornberry, a director at Denali Therapeutics Inc. (NASDAQ:DNLI), sold 11,439 shares of common stock for $261,928 on September 2, 2026, under a Rule 10b5-1 trading plan. Despite the stock being up significantly year-to-date and over the past year, Denali Therapeutics recently reported a significant revenue miss for Q2 2026, though its stock increased after hours following the launch of its first approved medicine, AVLAYAH. InvestingPro analysis suggests DNLI is undervalued and holds more cash than debt.
Denali Therapeutics director sells $261,928 in stock By Investing.com
Nancy Thornberry, a director at Denali Therapeutics Inc. (NASDAQ:DNLI), sold 11,439 shares of common stock totaling $261,928 on September 2, 2026. These sales were executed under a Rule 10b5-1 trading plan, with the stock currently trading at $22.28. Despite a recent revenue miss, Denali Therapeutics has launched its first approved medicine, AVLAYAH, and analysts view the stock as undervalued.
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
Denali Therapeutics Director Nancy Thornberry sold 11,439 shares of the company's stock on September 2, 2026, totaling $261,929. This transaction was disclosed in a recent SEC filing. The article notes that a premium subscription is required to view the full MT Newswires report.
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale
Alexander Schuth, an officer at Denali Therapeutics Inc. (DNLI), plans to sell 2,768 shares of common stock under Rule 144, valued at approximately $65,767.68. The shares are related to Restricted Stock Units acquired on August 9, 2026, with the proposed sale date set for September 1, 2026, on NASDAQ. This filing provides transparency regarding the insider's intention to sell, impacting the company's public share supply.
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale
Denali Therapeutics Inc. director Nancy Thornberry has filed a Rule 144 notice to sell 11,439 shares of common stock, valued at $266,128.34, through Morgan Stanley Smith Barney LLC on NASDAQ. These shares were acquired from the company via vesting restricted stock units between January 8, 2024, and May 31, 2025. The notice date for this proposed sale is September 2, 2026.
Understanding the Setup: (DNLI) and Scalable Risk
This article provides an analysis of Denali Therapeutics Inc. (NASDAQ: DNLI) based on AI-generated signals and institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with specific entry and exit points, targets, and stop losses for various risk profiles. The analysis also details support and resistance levels across different time horizons.
Denali Therapeutics (DNLI) Stock Dropped, So Why Is It Drawing Fresh Attention?
The provided content does not contain an article. It appears to be a navigation menu and footer content from a website called Sahm Capital Financial Company, along with image links. Therefore, no summary of an article can be generated.
Denali Therapeutics’ brain-crossing drug hits market
Denali Therapeutics has reported its first quarterly revenue of $3.6 million from AVLAYAH, a drug for Hunter syndrome that uses its Enzyme Transport Vehicle (ETV) technology to cross the blood-brain barrier. The company expects significant revenue growth for AVLAYAH, guiding $10-12 million for the next quarter, and has secured coverage for over 50% of US commercial lives and 14 state Medicaid programs. Beyond AVLAYAH, Denali is advancing two Alzheimer's drug candidates into clinical development, DNL628 and DNL921, with initial data expected in 2027.
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
B. Riley has increased its price target for Denali Therapeutics to $35 from $30, while reiterating a "Buy" rating for the biopharmaceutical company. The adjustment reflects B. Riley's continued positive outlook on Denali Therapeutics, which specializes in developing biotherapeutics for neurological diseases. Other financial institutions like UBS and Wedbush have also recently adjusted their price targets for Denali Therapeutics, generally maintaining positive ratings.
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC
Great Lakes Advisors LLC has purchased a new stake of 145,045 shares in Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $3,731,000 during the second quarter. Other institutional investors have also adjusted their holdings in Denali Therapeutics, and the company's stock has a "Moderate Buy" consensus rating from analysts with a target price of $35.92. Denali Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI
Bank of America Corp DE increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 21.7% in the first quarter, now holding 1.13 million shares valued at approximately $21.8 million. Institutional investors collectively own 92.92% of DNLI, and analysts maintain a "Moderate Buy" rating with an average target price of $35.92. Despite missing EPS estimates, Denali exceeded revenue expectations and continues to develop therapies for neurodegenerative diseases.
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report
Denali Therapeutics (DNLI) reported Q2 2026 revenue of US$3.6 million and a net loss of US$127.55 million. While the company's shares have shown strong recent momentum, trading at US$24.40, there are conflicting views on its valuation, with one narrative suggesting it's 41.9% undervalued at $42.00, while a DCF model indicates it's expensive at its current price. The company's valuation is heavily influenced by the performance of its AVLAYAH product and the pipeline risks.
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI
SCS Capital Management LLC has acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 197,998 shares valued at approximately $5.1 million. This makes them a new institutional investor in the biopharmaceutical company, which has seen significant interest from other large institutional investors as well. Denali Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with a target price of $35.92, despite a recent earnings per share miss.
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund
Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, Watts maintains significant direct and indirect ownership in the company through a family trust and directly held shares, including unvested RSUs.
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics reported Q2 2026 earnings, highlighting its transition to a commercial-stage company following the successful launch of AVLAYAH, a new therapy for Hunter syndrome. The company achieved $3.6 million in net product revenue in its first full commercial quarter and provided Q3 guidance of $10 million to $12 million due to strong demand and expanding payer coverage. Denali also advanced its Alzheimer's disease programs, DNL628 and DNL921, into clinical development, with initial data expected in 2027, and maintains a strong financial position with over $1.1 billion in cash and marketable securities.
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock
Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded expectations, and the stock is trading near its 52-week high of $27.30. Analysts maintain a "Moderate Buy" rating with an average price target of $35.92, indicating potential upside.
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI
Sei Investments Co. has acquired 52,235 shares of Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $1.0 million, contributing to institutional investors' 92.92% ownership of the company. Despite reporting a quarterly loss of $0.68 per share, Denali's revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $35.92. The stock opened at $25.27 and saw a 2.3% increase.
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI
E. Ohman J or Asset Management AB recently acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 160,000 shares valued at approximately $4.1 million, giving them a 0.10% stake in the company. Institutional investors collectively own 92.92% of DNLI, with several other hedge funds also adjusting their positions. Analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $35.92, despite the company reporting a quarterly loss of $0.68 per share, which missed estimates.
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction
Baillie Gifford reduced its stake in Denali Therapeutics Inc (DNLI) by 106,249 shares on June 30, 2026, lowering its total holdings to 11,960,230 shares. This transaction, representing a minor -0.88% change in the firm's portfolio, reflects a continued focus on long-term growth by the century-old investment firm. Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases, faces financial challenges with a low GF Score and profitability rank, despite strong momentum and low bankruptcy risk.
Denali climbs past Avlayah expectations with $3.6M in revenue
Denali Therapeutics has exceeded analyst expectations with its new Hunter syndrome therapy, Avlayah, reporting $3.6 million in revenue during its first quarter on the market, significantly surpassing the anticipated $1.3 million. The company has raised its third-quarter revenue guidance to $10-$12 million, driven by strong patient uptake, particularly switches from Takeda's Elaprase. Avlayah marks the first new treatment for Hunter syndrome in 20 years and also represents the first approval for Denali’s TransportVehicle blood-brain barrier technology, with projections for it to reach blockbuster status globally.
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI
The Manufacturers Life Insurance Company significantly reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 31.9% in the first quarter, selling 58,796 shares and retaining 125,442 shares valued at approximately $2.4 million. Despite this, institutional investors collectively own 92.92% of the stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $35.92, exceeding the current share price of $24.83. Denali, a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, reported a wider-than-expected quarterly loss but surpassed revenue estimates.
(DNLI) Movement Within Algorithmic Entry Frameworks
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models, highlighting strong sentiment across all time horizons and an exceptional 41.9:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes sophisticated risk management and multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks.
Denali Therapeutics earnings on deck: First drug sales in focus
Denali Therapeutics (DNLI) is set to report its second-quarter earnings, with investors keenly focused on the initial sales performance of its Hunter syndrome therapy, AVLAYAH, which received FDA approval in March. Analysts anticipate a loss of 71 cents per share on revenue of $2.17 million, a significant increase from the previous quarter's zero revenue. Beyond sales, key areas of interest include updates on the company's neurodegenerative pipeline and further validation of its proprietary TransportVehicle technology.
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue
Denali Therapeutics (DNLI) saw its shares rise 7.9% after reporting Q2 2026 results, which included the first full-quarter commercial revenue from its drug AVLAYAH. Despite a net loss of US$127.55 million, the company highlighted growing operational and financial platforms due to AVLAYAH's launch, expanded payer access, and over US$1.10 billion in pro forma cash. The article discusses Denali's investment narrative, emphasizing the need for its TransportVehicle platform to translate science into a viable business, while acknowledging risks like commercialization execution and clinical setbacks.
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" consensus rating for Denali Therapeutics Inc. (NASDAQ:DNLI), with an average 12-month price target of $35.92, significantly above its current trading price. This comes despite the company reporting a quarterly loss of $0.68 per share, which missed consensus estimates, although its revenue exceeded expectations. Institutional investors hold a substantial 92.92% stake in the company, with notable increases in holdings from firms like Goldman Sachs.
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $35.92. Despite missing quarterly EPS estimates, Denali reported higher-than-forecast revenue, and institutional investors hold a significant portion of its stock. The company is trading at $24.83, with a market capitalization of approximately $3.94 billion.
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside
The average 12-month price target for Denali Therapeutics Inc. (DNLI) stock has been raised to $35.44 from $34.31 by 16 analysts, with forecasts ranging from $27 to $42 per share. This new target implies a potential upside of approximately 43% from its August 6 closing price. The consensus rating among 20 analysts remains a "Buy," with 19 Buys and 1 Hold.
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics (DNLI) reported a narrower Q2 2026 loss of 68 cents per share, surpassing the Zacks Consensus Estimate. The company's net product revenues reached $3.6 million, driven by the strong initial commercial sales of its newly FDA-approved drug, Avlayah, for Hunter Syndrome. Denali's stock has seen a significant gain year-to-date, and it projects Avlayah net product revenues of $10.0 million to $12.0 million for Q3 2026.
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
Wedbush has increased its price target on Denali Therapeutics Inc. (DNLI) to $27 from $26, while maintaining an Outperform rating. This adjustment comes shortly after Denali Therapeutics reported its Q2 2026 earnings, posting a loss of $0.68 per share but exceeding revenue expectations with $3.6 million. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher for $195 million, contributing to recent financial activities.
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics reported strong financial results for Q2 2026, driven by the successful launch of AVLAYAH™, which generated $3.6 million in net product revenue. The company also announced the advancement of two Alzheimer’s disease programs into clinical development and received $195 million from the sale of a Priority Review Voucher, boosting its cash reserves to over $1.1 billion. Denali's TransportVehicle™ platform continues to be a key asset, enabling the delivery of biotherapeutics across the blood-brain barrier.
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary
Denali Therapeutics Inc. reported second-quarter 2026 financial results, marking its first product revenue of $3.6M from the commercial launch of AVLAYAH, despite continuing to incur a net loss and negative EPS. The company highlighted AVLAYAH's accelerated FDA approval and initial U.S. sales, operational scale-up with a new biomanufacturing facility, and progress in multiple clinical programs. Strategic financings, including the sale of a priority review voucher and a royalty transaction, also supported commercial and R&D activities.
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds
Denali Therapeutics reported a Q2 2026 revenue miss, posting $3.6 million against an expected $11.94 million, and a wider-than-forecast loss of $0.68 per share. Despite the miss, the stock rose in after-hours trading as investors focused on the early, encouraging commercial launch of AVLAYAH, the company's first approved medicine, which generated $3.6 million in its first full commercial quarter. Denali provided Q3 revenue guidance for AVLAYAH between $10 million and $12 million, signaling accelerated growth driven by expanding payer coverage and physician adoption.
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M
Denali Therapeutics Inc. (DNLI) reported Q2 revenue of $3.6 million, significantly surpassing FactSet's estimated $2.2 million. The company is focused on developing biotherapeutics that cross the blood-brain barrier for treating neurological conditions and other diseases. Denali also anticipates Q3 revenue to range between $10.0 million and $12.0 million.
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH
Denali Therapeutics reported a Q2 2026 net loss of $127.6 million and $3.6 million in net product revenue from its newly launched therapy, AVLAYAH, for Hunter syndrome. The company also announced the discontinuation of a Parkinson's disease program (BIIB122/DNL151) after its Phase 2b study failed to meet endpoints, while securing $200 million in synthetic royalty funding and selling a Rare Pediatric Disease Priority Review Voucher for $195 million.
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) reported a Q2 loss of $0.68 per share, outperforming the Zacks Consensus Estimate of a $0.72 loss. The company also surpassed revenue estimates with $3.6 million, significantly higher than zero revenues a year ago. Despite outperforming the market year-to-date, Denali currently holds a Zacks Rank #4 (Sell) due to unfavorable earnings estimate revisions.
Baillie Gifford & Co (DNLI) reports 7.54% stake in Denali Therapeutics common stock
Baillie Gifford & Co has reported a 7.54% stake in Denali Therapeutics (DNLI) common stock, according to an amended Schedule 13G filing. The investment adviser beneficially owns 11,960,230 shares, holding sole voting power over 11,915,890 shares and sole dispositive power over all 11,960,230 shares as of June 30, 2026. These shares are managed on behalf of various investment advisory clients.
How (DNLI) Movements Inform Risk Allocation Models
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models to inform risk allocation. It highlights divergent sentiment across time horizons, indicating choppy conditions, and points out a significant 41.3:1 risk-reward setup. The analysis provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Denali Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Denali Therapeutics (NASDAQ: DNLI) has approximately 516 employees worldwide as of March 2026, marking a 14.9% growth since 2023. The company is actively hiring, with 38 job postings in 2026, though this represents a 40% decline from 2025. The workforce is primarily located in the United States, with an average salary of $195,010 and a median employee tenure of 2.3 years.
Denali Therapeutics Completes Sale of Rare Pediatric Disease Priority Review Voucher
Denali Therapeutics announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The sale generated gross proceeds of $95 million, which the company intends to use to support its pipeline and operations. This strategic move highlights Denali's efforts to maximize its assets and fund future drug development.
Denali Therapeutics sells priority review voucher for $195 million gross proceeds
Denali Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds to a large pharmaceutical company. This voucher was granted after the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026. The transaction officially closed on July 27, 2026.
Denali Therapeutics Inc (DNLI) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Denali Therapeutics Inc (DNLI), encompassing operating, investing, and financing activities. It presents key financial data, including net income, capital expenditures, and free cash flow over several fiscal quarters. The report also includes FAQs defining different types of cash flow and their significance for investors.
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Denali Therapeutics will report its second quarter 2026 financial results and provide business highlights on August 6, 2026. The company plans to issue a press release after market close, followed by a conference call and webcast for investors and the public. This event will cover the company's financial performance and recent developments.
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier
Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The company is known for developing biotherapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform.
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Denali Therapeutics Inc. announced it will report its Q2 2026 financial results and business highlights on Thursday, August 6, 2026. The report will be followed by a conference call and webcast hosted by Denali's management to discuss the results and provide a general business update. The biotechnology company focuses on developing biotherapeutics for neurodegenerative diseases and lysosomal storage disorders.
DNLI|Denali Therapeutics Inc|Price:23.570|Chg%:+0.460
This article provides a comprehensive stock analysis of Denali Therapeutics Inc (DNLI), highlighting its relatively weak fundamentals but high growth potential. The company is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and multiple 'Buy' analyst ratings. Denali Therapeutics is focused on developing therapies for neurodegenerative and lysosomal storage diseases, leveraging its Transport Vehicle (TV) technology.
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Denali Therapeutics Inc (DNLI), listing its major shareholders and their respective proportions, including Baillie Gifford & Co., BlackRock Institutional Trust Company, N.A., and T. Rowe Price Investment Management, Inc. It also breaks down shareholder types by proportion, such as investment advisors and hedge funds. Furthermore, the article provides institutional shareholding trends over several quarters and lists related ETFs holding DNLI shares.
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI
This article provides a brief overview of Denali Therapeutics Inc. (NASDAQ: DNLI) financials, specifically focusing on its revenue breakdown. It highlights that detailed revenue segmentation by source and country is available, powered by data from ICE Data Services and FactSet. The content is primarily an introductory page from TradingView, offering access to more in-depth financial data.
